63
Participants
Start Date
May 3, 2021
Primary Completion Date
April 18, 2022
Study Completion Date
April 18, 2022
Furoscix Infusor
Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
Icahn School of Medicine at Mount Sinai, New York
Lancaster General Hospital, Lancaster
Cone Health Medical Group, Greensboro
University Hospital - Augusta, Augusta
First Coast Cardiovascular Institute, Jacksonville
Cardiology Consultants, Pensacola
University of Florida, Gainesville
Elite Cardiac Research, Hialeah
Aventura Clinical Research, LLC, Aventura
James A. Haley Veerans Hospital, Tampa
The Heart Center Research, LLC, Huntsville
Heart Group of Eastern Shore, Fairhope
Michigan Heart, Ypsilanti
University of Wisconsin, Madison
Advocate Health and Hospitals, Downers Grove
UnityPoint Health - Methodist Hospital, Peoria
St. Louis Heart and Vascular, St Louis
Hartford Hospital, Hartford
scPharmaceuticals, Inc.
INDUSTRY